Sanofi Completes Acquisition of Inhibrx, Inc.

Paris, May 30, 2024. Sanofi announced the completion of the acquisition of Inhibrx, Inc. This transaction integrates SAR447537 into Sanofi's portfolio in rare diseases.

SAR447537, a human recombinant protein, could normalize alpha-1-antitrypsin levels in deficient patients with monthly doses. Alpha-1-antitrypsin deficiency is a rare hereditary disease primarily affecting the lungs. This treatment could reduce inflammation and prevent worsening of respiratory function.

Inhibrx shareholders approved the transaction valued at $1.7 billion, including a contingent value right of $5.00 per share. Inhibrx thus becomes a subsidiary of Sanofi.

Prior to this acquisition, Inhibrx spun off Inhibrx Biosciences, transferring 92% of the shares to the former shareholders and divesting assets unrelated to SAR447537. Shares of Inhibrx Biosciences are now listed on the NASDAQ.